Nextage Therapeutics Ltd (NXTG) - Total Liabilities
Based on the latest financial reports, Nextage Therapeutics Ltd (NXTG) has total liabilities worth ILA5.89 Million ILA (≈ $15.79K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Nextage Therapeutics Ltd growing its equity to track the company's year-over-year net asset growth rate.
Nextage Therapeutics Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Nextage Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Nextage Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Nextage Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FIRST LITHIUM MINERALS
F:X28
|
Germany | €531.58K |
|
Thunderstruck Resources Ltd
V:AWE
|
Canada | CA$747.18K |
|
Witbe Net SA
PA:ALWIT
|
France | €16.43 Million |
|
Till Capital Ltd
V:TIL
|
Canada | CA$147.08K |
|
Lupatech S.A
SA:LUPA3
|
Brazil | R$405.63 Million |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
USA | $1.65 Million |
|
Reviva Pharmaceuticals Holdings Inc.
NASDAQ:RVPH
|
USA | $7.28 Trillion |
Liability Composition Analysis (2017–2024)
This chart breaks down Nextage Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Nextage Therapeutics Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 16.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nextage Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nextage Therapeutics Ltd (2017–2024)
The table below shows the annual total liabilities of Nextage Therapeutics Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA5.89 Million ≈ $15.79K |
+53.68% |
| 2023-12-31 | ILA3.83 Million ≈ $10.27K |
+97.73% |
| 2022-12-31 | ILA1.94 Million ≈ $5.20K |
-48.40% |
| 2021-12-31 | ILA3.76 Million ≈ $10.07K |
+43.36% |
| 2020-12-31 | ILA2.62 Million ≈ $7.02K |
+11.49% |
| 2019-12-31 | ILA2.35 Million ≈ $6.30K |
-67.02% |
| 2018-12-31 | ILA7.12 Million ≈ $19.10K |
-10.46% |
| 2017-12-31 | ILA7.96 Million ≈ $21.33K |
-- |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.